Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA)

What We Do:

The DPMCDA plans and directs studies necessary to identify, evaluate, and develop medications to treat substance use disorders (SUDs). The Division develops and administers a program of basic and clinical research to develop innovative pharmacological (both chemical and biological) approaches to treat SUDs . This program is implemented through collaborations with academia, industry (pharmaceutical and biotechnology companies), and other government institutions (e.g., the Veterans Administration and the FDA). The Division also coordinates and provides leadership in the area of medical conditions associated with SUDs, including but not limited to HIV/AIDS.

Research Programs:

• The Addiction Treatment Discovery Program (ATDP)
• Cocaine Clinical Trials Program (CCTP)
• Opiate Clinical Trials Program (OCTP)
• Methamphetamine Clinical Trial Group Program (MCTGP)
• Medical Consequences of Drug Abuse and Co-occurring Infections Program
• Medications Research Grants
• Immunotherapy

Division Listings:

• Office of the DPMCDA Director (OD)
• Medical Consequences Branch (MCB)
• Chemistry and Pharmaceutics Branch (CPB)
• Medications Discovery and Toxicology Branch (MDTB)
• Regulatory Affairs Branch (RAB)
• Medications Research Grants Branch (MRGB)
• Clinical/Medical Branch(CMB)

Staff Listings:

• Staff Listings

Mailing Address:

Division of Pharmacotherapies & Medical Consequences of Drug Abuse
National Institute on Drug Abuse
6001 Executive Boulevard
Room 4123, MSC 9551
Bethesda, MD 20892-9551
(301) 443-6173 (phone)
(301) 443-2599 (fax)